His primary scientific interests are in Internal medicine, Gastroenterology, Ulcerative colitis, Inflammatory bowel disease and Crohn's disease. Subrata Ghosh combines subjects such as Placebo, Surgery and Immunology with his study of Internal medicine. His research investigates the connection with Gastroenterology and areas like Crohn's Disease Activity Index which intersect with concerns in Methotrexate and Adverse effect.
The Ulcerative colitis study which covers Colitis that intersects with Mesalazine and Pharmacology. In his study, which falls under the umbrella issue of Inflammatory bowel disease, Combination therapy is strongly linked to Review article. Crohn's disease is the subject of his research, which falls under Disease.
The scientist’s investigation covers issues in Internal medicine, Gastroenterology, Ulcerative colitis, Inflammatory bowel disease and Crohn's disease. His study in Internal medicine is interdisciplinary in nature, drawing from both Placebo and Surgery. His studies in Gastroenterology integrate themes in fields like Colonoscopy, Azathioprine and Endoscopy.
His Ulcerative colitis study combines topics from a wide range of disciplines, such as Chromoendoscopy, Adalimumab, Infliximab and Colitis. His Inflammatory bowel disease study combines topics in areas such as Physical therapy and Intensive care medicine. His research on Crohn's disease often connects related areas such as Immunology.
Internal medicine, Inflammatory bowel disease, Ulcerative colitis, Crohn's disease and Gastroenterology are his primary areas of study. His study explores the link between Internal medicine and topics such as Placebo that cross with problems in Adverse effect. His studies deal with areas such as Colorectal cancer, Dysplasia and Cohort as well as Inflammatory bowel disease.
His Ulcerative colitis research includes elements of Colonoscopy, Chromoendoscopy and Histology. His Crohn's disease study frequently links to other fields, such as Intensive care medicine. Subrata Ghosh works mostly in the field of Gastroenterology, limiting it down to topics relating to Calprotectin and, in certain cases, Feces, as a part of the same area of interest.
Subrata Ghosh focuses on Inflammatory bowel disease, Internal medicine, Crohn's disease, Ulcerative colitis and Gastroenterology. His research on Inflammatory bowel disease concerns the broader Disease. As a member of one scientific family, he mostly works in the field of Internal medicine, focusing on Endocrinology and, on occasion, Inflammation, Occludin and Experimental colitis.
His work in Crohn's disease covers topics such as Adverse effect which are related to areas like Placebo, Ustekinumab, Clinical endpoint and Crohn's Disease Activity Index. His Ulcerative colitis research integrates issues from Adalimumab, Infliximab, Granuloma, Paneth cell and Cohort. His Gastroenterology research is multidisciplinary, incorporating elements of Randomized controlled trial, Maintenance therapy and Induction therapy.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Increasing Incidence and Prevalence of the Inflammatory Bowel Diseases With Time, Based on Systematic Review
Natalie A. Molodecky;Ing Shian Soon;Doreen M. Rabi;William A. Ghali.
Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies
Siew C Ng;Hai Yun Shi;Hai Yun Shi;Nima Hamidi;Fox E Underwood.
The Lancet (2017)
Natalizumab for Active Crohn's Disease
Subrata Ghosh;Eran Goldin;Fiona H. Gordon;Helmut A. Malchow.
The New England Journal of Medicine (2003)
Ustekinumab induction and maintenance therapy in refractory Crohn's disease.
William J. Sandborn;Christopher Gasink;Long Long Gao;Marion A. Blank.
The New England Journal of Medicine (2012)
Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis.
Remo Panaccione;Subrata Ghosh;Stephen Middleton;Juan R. Márquez.
European evidence-based Consensus on the management of ulcerative colitis: Current management.
S. P. L Travis;E. F Stange;M Lemann;T Oresland.
Journal of Crohns & Colitis (2008)
Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis.
William J. Sandborn;Subrata Ghosh;Julian Panes;Ivana Vranic.
The New England Journal of Medicine (2012)
Increased capsaicin receptor TRPV1-expressing sensory fibres in irritable bowel syndrome and their correlation with abdominal pain
Ayesha Akbar;Yiangos Yiangou;Paul Facer;Julian R F Walters.
Risk of Surgery for Inflammatory Bowel Diseases Has Decreased Over Time: A Systematic Review and Meta-analysis of Population-Based Studies
Alexandra D. Frolkis;Jonathan Dykeman;María E. Negrón;Jennifer deBruyn.
Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial
C S J Probert;S D Hearing;S Schreiber;T Kühbacher.
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: